✦ LIBER ✦

Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia

✍ Scribed by A. D. Shapiro; J. Korth-Bradley; M.-C. Poon

Book ID: 108772501
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 212 KB
Volume: 11
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2005.01149.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Implications of coagulation factor VIII

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

✍ P. W. COLLINS; K. FISCHER; M. MORFINI; V. S. BLANCHETTE; S. BJÖRKMAN; ON BEHALF 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

Prophylactic treatment of haemophilia pa

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres

✍ M. MORFINI; G. AUERSWALD; R. A. KOBELT; G. F. RIVOLTA; J. RODRIGUEZ-MARTORELL; F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB

Physicians’ preferences towards coagulat

Physicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment

✍ WC LEE; A. V. JOSHI; S. WOOLFORD; M. SUMNER; M. BROWN; N. HADKER; C. L. PASHOS 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

Pharmacokinetics of Optivate®, a high-pu

Pharmacokinetics of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A

✍ A. DMOSZYNSKA; A. HELLMANN; T. BAGLIN; D. O’SHAUGNESSY; J. TRELINSKI; K. KULICZK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

The economic impact of factor VIII inhib

The economic impact of factor VIII inhibitors in patients with haemophilia

✍ R. L. Bohn; L. M. Aledort; K. G. Putnam; B. M. Ewenstein; H. Mogun; J. Avorn 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

**Summary.** The impact on the cost of care for haemophilia patients with inhibitors is not well defined. To quantify the effect on health care expenditures associated with inhibitors to factor VIII (FVIII) or FIX, we conducted a retrospective cohort study examining product use and outcomes in adult

Prevalence and risk factors of cardiovas

Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US)

✍ A. A. SHARATHKUMAR; J. M. SOUCIE; B. TRAWINSKI; A. GREIST; A. D. SHAPIRO 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB